United Therapeutics Corporation Current Liabilities
United Therapeutics Corporation (UTHR) had Current Liabilities of $607.80 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $607.80M.
- 2026-03-31: Liabilities, Current $599.10M.
- 2025-12-31: Liabilities, Current $560.60M.
- 2025-09-30: Liabilities, Current $546.30M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $607.80M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $599.10M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $560.60M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $546.30M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $527.10M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $721.50M 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $738.10M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $873.40M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $832.30M 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $860.60M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $804.40M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $744.10M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $370.30M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $324.60M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $343.20M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $315.90M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $331.50M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $292.60M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $305.40M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $320.00M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $311.40M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $302.40M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $323.30M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $258.90M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $255.00M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $207.30M 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $463.00M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $469.90M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $463.50M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $270.00M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $276.60M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $372.40M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $350.00M 10-Q · filed 2018-08-01 | |
| 2018-03-31 | $318.40M 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $444.70M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $789.40M 10-Q · filed 2017-10-25 | |
| 2017-06-30 | $838.80M 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $427.70M 10-Q · filed 2017-04-26 | |
| 2016-12-31 | $332.50M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $314.60M 10-Q · filed 2016-10-27 | |
| 2016-06-30 | $292.40M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $357.10M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $440.70M 10-K · filed 2017-02-22 | $440.82M 10-K · filed 2016-02-25 |
| 2015-09-30 | $557.34M 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $542.41M 10-Q · filed 2015-07-28 | |
| 2015-03-31 | $646.75M 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $504.31M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $760.65M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $659.07M 10-Q · filed 2014-07-29 | |
| 2014-03-31 | $658.53M 10-Q · filed 2014-04-29 | |
| 2013-12-31 | $687.67M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $468.91M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $412.23M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $176.60M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $176.75M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $227.62M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $187.66M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $175.54M 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $212.58M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $424.95M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $453.54M 10-Q · filed 2011-07-28 | |
| 2011-03-31 | $441.95M 10-Q · filed 2011-04-28 | |
| 2010-12-31 | $428.69M 10-K · filed 2012-02-28 | |
| 2010-09-30 | $397.46M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $365.72M 10-Q · filed 2010-07-28 | |
| 2009-12-31 | $330.19M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |